Lucira Health

Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company was founded by Debkishore Mitra, John Robert Waldeisen and Benjamin Ross in 2013 and is headquartered in Emeryville, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand.

NEW YORK, Dec. 20, 2021 /PRNewswire/ -- WHY: New York, N.Y., December 19, 2021.

TOP RANKED ROSEN LAW FIRM Encourages Lucira Health, Inc. Investors with Losses to Inquire About Class Action Investigation - LHDX

Los Angeles, California--(Newsfile Corp. - December 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lucira Health, Inc. ("Lucira" or "the Company") (NASDAQ: LHDX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Lucira issued a press release during pre-market hours on October 8,...

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Lucira Health, Inc. and Encourages Investors with Losses to Contact the Firm

Lucira Health's (LHDX) CEO Erik Engelson on Q3 2021 Results - Earnings Call Transcript

EMERYVILLE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the third quarter ended September 30, 2021 and provided business updates.

Lucira Health Announces Third Quarter 2021 Financial Results and Provides Business Update

LOS ANGELES--(BUSINESS WIRE)---- $LHDX #LHDX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lucira Health, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lucira Health, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $LHDX #LHDX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lucira Health, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lucira Health, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Lucira Health, Inc. (NASDAQ: LHDX) resulting from allegations that Lucira may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Lucira securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Ro

LHDX EQUITY ALERT: Rosen Law Firm Encourages Lucira Health, Inc. Investors with Losses to Inquire About Class Action Investigation – LHDX

EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report third quarter 2021 financial results on, Thursday, November 11, 2021. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Lucira Health to Announce Third Quarter 2021 Financial Results

This FDA Emergency Use Authorization (“EUA”) first PCR quality, single-use, COVID-19 at home, self-test kit can again be purchased via the Company's website

LUCIRA™ CHECK IT COVID-19 Test Kit is Available for Online Purchase

Singapore Health Sciences Authority issues approval by its Pandemic Special Access Route (PSAR) for the LUCIRA CHECK IT COVID-19 Test Kit. Lucira has partnered with Labgistics Asia Pte Ltd for the importation and distribution of its products in Singapore. Singapore Health Sciences Authority issues approval by its Pandemic Special Access Route (PSAR) for the LUCIRA CHECK IT COVID-19 Test Kit. Lucira has partnered with Labgistics Asia Pte Ltd for the importation and distribution of its products in Singapore.

LUCIRA™ HEALTH COVID-19 Test Approved for Sale in Singapore

EMERYVILLE, Calif., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today commented on the recent recall of the FLOQSwabs by supply partner Copan Italia SPA, or Copan.

LUCIRA™ HEALTH Provides Statement on Copan's Recall of its FLOQSwabs

Veteran operations expert joins Lucira's management team Veteran operations expert joins Lucira's management team

LUCIRA™ HEALTH Hires Tony Allen as Chief Operations Officer

EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced life science professional Ghazi Kashmolah has joined the company as Chief Quality Officer and Executive Vice President Regulatory Affairs. “Ghazi is a strong addition to Lucira's executive leadership team, and we are delighted to have him

LUCIRA™ HEALTH Hires Ghazi Kashmolah as Chief Quality Officer and EVP Regulatory Affairs

bluebird bio

Vertex Pharmaceuticals

These biotech stocks might be down, but they're not out.

3 Beaten-Down Biotech Stocks to Buy Right Now

Lucira Health Inc (NASDAQ: LHDX) reported sales of $12.4 million in Q2, the firm's second full quarter of commercial activity, beating the consensus estimate of $8 million. Sales increased 175% sequentially, propelled by the volume of Lucira Check It COVID-19 Test Kit sales through the OTC indication, increased customer contracts, and international demand.

Lucira Health Stock Soars After Q2 Sales Jump 175% Sequentially

Lucira Health's (LHDX) CEO Erik Engleson on Q2 2021 Results - Earnings Call Transcript

EMERYVILLE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the second quarter ended June 30, 2021.

Lucira Health Announces Second Quarter 2021 Financial Results

Bed Bath & Beyond

The stocks have huge upside potential that investors are overlooking.

2 Under-the-Radar Stocks to Buy Now

Abbott Labs

BioNTech SE

Fulgent Genetics

Roche Holding AG

Despite easing restrictions, COVID is going to be around a lot longer than many think.

5 Stocks to Own for the Surge in Coronavirus Variants

The company may be the beneficiary of another social media-inspired buying frenzy.

Why Lucira Health Is Rocketing Higher Today

EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced medtech veteran Kevin Collins has joined the company as Chief Revenue Officer with global revenue responsibility. Collins began his medical technology career with Lumenis Ltd., a medical equipment and laser technologies company, where he rose from Area Sales Manager to

LUCIRA™ HEALTH Hires Chief Revenue Officer Kevin Collins

This start-up's over-the-counter COVID-19 tests could be a huge hit.

Is Lucira Health a Good Stock to Buy Right Now?

Lucira Health, Inc. (LHDX) CEO Erik Engelson on Q1 2021 Results - Earnings Call Transcript

EMERYVILLE, Calif, May 13, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health," "Lucira" or the "Company") (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the first quarter ended March 31, 2021.

Lucira Health Announces First Quarter 2021 Financial Results

Second Sight Medical Products

Ra Medical Systems Inc

Second Sight Medical Products, Inc. (NASDAQ: EYES), Lucira Health, Inc. (NASDAQ: LHDX) and Ra Medical Systems, Inc. (NYSE: RMED) were among the biggest health care gainers Wednesday. Second Sight Rallies On Positive Results For Visual Prosthesis: Second Sight, which makes implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced two-year results for the early feasibility study of its Orion Visual Cortical Prosthesis.

News for Lucira Health Stock (LHDX)